A new approach to accelerating stem cell differentiation, critical for the next generation of cell therapies, has just received a significant boost. Syntax Bio, the synthetic biology company behind the Cellgorithmâ„¢ platform, announced it has closed a $4.0M Series A funding round.
The company's proprietary CRISPR-based system aims to transform regenerative medicine by replacing slow, labor-intensive processes with a rapid, programmable method that mimics human development. This promises to make cellular generation more reliable and scalable at unprecedented speed, opening new avenues across the biotechnology industry.
.png&w=3840&q=75)
